Recent advances in spatial multi-omics have improved our ability to study tissue architecture, cellular heterogeneity, and cell-cell interactions within the tumor microenvironment. Xenium and Visium HD provide complementary strengths: Xenium offers true single-cell and subcellular spatial resolution but is limite...
Yang Liu, Akiko Sagara, Ji-Min Min et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy and has long been regarded as a therapeutic "drug graveyard", with modest gains from cytotoxic combination chemotherapy and numerous novel agents failing to show benefit in clinical trials. The quest to directly target RAS has moved from concept...
Peter Y. Yu, Paul E. Oberstein, A. Maitra et al.· Clinical Cancer Research· 0 citations
Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
S. Haldar, Meredith Wetzel, Jia-Yun Lu et al.· Clinical Cancer Research· 0 citations
This review highlights emerging evidence from spatial profiling studies demonstrating that PDAC and its precursor lesions are not just a simple mixture of malignant and stromal cells but rather a structured ecosystem with spatially distinct immune and fibroblast niches.
S. Bae, A. Tsirigos, Ji-Min Min et al.· Experimental and Molecular M...· 0 citations
It is shown that KRAS targeting with MRTX1133 or Daraxonrasib specifically synergizes with anti-CTLA4, but not other immune checkpoint inhibitors, in inducing tertiary lymphoid structures and promoting anti-tumor immune responses in preclinical pancreatic cancer models.
Krishnan K. Mahadevan, A. S. Maldonado, Bing-Rui Li et al.· Nature Communications· 0 citations
By integrating adaptive response to KRAS inhibition with anti-tumor immunity, AXL represents a mechanistically actionable vulnerability whose inhibition deepens and prolongs responses to both allele-specific and pan-KRAS-targeted therapies.
F. Thege, A. Kramer, Norbert Kreisz et al.· bioRxiv· 0 citations
Mediator complex kinase CDK8 is identified as a driver of resistance towards KRASG12D inhibition in pancreatic ductal adenocarcinoma (PDAC), promoting stromal remodeling and immunosuppression and CDK8 inhibition in resistant tumors re-primes PDAC to anti-CTLA-4 immunotherapy efficacy.
Kathleen M. McAndrews, Krishnan K. Mahadevan, Bingrui Li et al.· EMBO Journal· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
